FindTrial
Sign In

Dose minodronic acid for patients of differentiated thyroid carcinoma with TSH suppressive therapy after total-thyroidectomy prevent osteoporosis?

Dose minodronic acid for patients of differentiated thyroid carcinoma with TSH suppressive therapy after total-thyroidectomy prevent osteoporosis? - M.D.T Trial

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000025025
Enrollment
80
Registered
2016-11-28
Start date
2016-11-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients of differentiated thyroid carcinoma after total-thyroidectomy

Interventions

minodronic acid alfa calcidol

Sponsors

Department of Endocrine Surgery,Fujita-health University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1.Diagnosis of differentiated thyroid carcinoma by pathological examination 2.postmenopausal female 3. A:TSH <0.44ng/ml B:Serum calcium level 8.5~10.5mg/dl C:eGFR > 60ml/min

Exclusion criteria

Exclusion criteria: 1.bone fracture before thyroidectomy 2.family history of thighbone fracture 3.Administration of bisphosphonate before thyrodectomy 4.hyper-parathyroidism 5.hypo-parathyroidism after thyroidectomy

Design outcomes

Primary

MeasureTime frame
Bone mineral density of the lumbar vertebra and unilateral thigh bone( 6 month, 12month after administration)—

Countries

Japan

Contacts

Public ContactChikara Kagawa

Fujita-health University Endocrine Surgery

chikarak@fujita-hu.ac.jp0562-93-9033

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026